"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy (Q28317866)

Europe PubMed Central

PubMed ID

55599

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A55599

9 April 2022

J. D. Parkes

series ordinal

2

1 reference

Europe PubMed Central

PubMed ID

55599

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A55599

full work available at URL

9 April 2022

language of work or name

English

0 references

publication date

7 February 1976

0 references

https://api.elsevier.com/content/article/PII:S0140673676914161?httpAccept=text/xml

1 reference

10.1016/S0140-6736(76)91416-1

DOI

https://api.crossref.org/works/10.1016/S0140-6736(76)91416-1

https://api.elsevier.com/content/article/PII:S0140673676914161?httpAccept=text/plain

9 April 2022

1 reference

10.1016/S0140-6736(76)91416-1

DOI

https://api.crossref.org/works/10.1016/S0140-6736(76)91416-1

9 April 2022

0 references

1

0 references

issue

7954

0 references

page(s)

292-6

0 references

cites work

Aromatic Amino Acids and Modification of Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2876%2991416-1

7 January 2021

Long-term side-effects of levodopa.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2876%2991416-1

7 January 2021

Patterns of clinical response and plasma dopa levels in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2876%2991416-1

7 January 2021

"On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2876%2991416-1

7 January 2021

Plasma dopa concentrations and the "on-off" effect after chronic treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2876%2991416-1

7 January 2021

Injected apomorphine and orally administered levodopa in Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2876%2991416-1

7 January 2021

"On-Off" Phenomena Related to High Plasma Levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2876%2991416-1

7 January 2021

Tetrahydroisoquinoline alkaloids: in vivo metabolites of L-dopa in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2876%2991416-1

7 January 2021

Effects of L-dopa metabolites at a dopamine receptor suggest a basis for ‘on-off’ effect in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2876%2991416-1

7 January 2021

Start hesitation--a side effect of long-term levodopa therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2876%2991416-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2876%2991416-1

1 reference

7 January 2021

Letter: Diphasic dyskinesia during levodopa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2876%2991416-1

7 January 2021

Letter: Dyskinesias during levodopa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2876%2991416-1

7 January 2021

A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2876%2991416-1

7 January 2021

Bromocriptine in Parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2876%2991416-1

7 January 2021

Idiopathic parkinsonism treated with bromocriptine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2876%2991416-1

7 January 2021

Letter: Bromocriptine in parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2876%2991416-1

7 January 2021